Boston Therapeutics Announces Q4 and FY 2014 Financial Results and Corporate Update
MANCHESTER, NH -- (Marketwired) -- 03/27/15 -- Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer ...
Boston Therapeutics Expands Sugardown® License to Japan; Chinese Trial to Start
Boston Therapeutics and Advance Pharmaceutical Company (APC) announced today the expansion of their ...
Boston Therapeutics Measures the Impact of sugardown® Taken Before Sodas
On Tuesday, January 20, 2015, Boston Therapeutics, Inc. (BTHE-OTC) released additional trial results from its ...
Chewable Pill to Help Treat Type 2 Diabetes Receives IND Approval
This morning, pharmaceutical company Boston Therapeutics, Inc. (BTHE-OTC) reported that the U.S. Food and ...
New Study Measures Impact of OTC Supplement to Reduce Glucose and Insulin After Drinking Soda
Following Boston Therapeutics' (BTHE-OTC) early November announcement for the launch of sugardown® branding ...
Boston Therapeutics Announces North American Branding of sugardown®
Pharmaceutical company Boston Therapeutics, Inc. (BTHE-OTC) announced this morning that Benchworks SD, LLC ...
Expanding Boston Therapeutics' Medical Advisory Board and Patentable Uses of BTI-320
In addition to the leadership additions announced last week by Boston Therapeutics (BTHE-OTC), the company ...
Boston Therapeutics Ramps Up Sugardown®, Expands Board of Directors
Pharmaceutical company Boston Therapeutics (BTHE-OTC) announced this week the launch of a new commercial ...
Boston Therapeutics Strengthens its Medical Advisory Board
Boston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes ...
Boston Therapeutics Signs Agreement for Phase III Study of BTI-320
Boston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes, ...
NEW RESEARCH: August 2014 Update on Boston Therapeutics (BTHE)
We have published an updated report on pharmaceutical company, Boston Therapeutics, Inc. (BTHE-OTC). The ...
Boston Therapeutics $BTHE Announces Strategic Marketing Agreement for SUGARDOWN®
Boston Therapeutics (BTHE-OTC), a developer of compounds that address blood sugar management and inflammatory ...
Boston Therapeutics (BTHE-OTC) Inks Agreement with Patheon for BTI-320
Boston Therapeutics, Inc., along with its Hong Kong-based strategic partner Advance Pharmaceutical Company, ...
NEW RESEARCH: 60-Page Executive Informational Overview on Boston Therapeutics (BTHE) Just Added
This afternoon, we released a 60-page Executive Informational Overview on New Hampshire-based Boston ...